ScholarWorks@Gachon: Ahn, Hee Kyung

Detailed Information

Ahn, Hee Kyung (안희경)

College of Medicine (Department of Medicine)

Research Area: 의학, 종양학

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:9||prognosis:7||chemotherapy:6||Chemotherapy:5||sarcopenia:5||nonsmall cell lung cancer:5||Xray computed:4||Gemcitabine:4||Nonsmall cell lung cancer:4||lung cancer:4||Docetaxel:4||Neoplasms:3||Nextgeneration sequencing:3||Palbociclib:3||realworld data:3||Sarcopenia:3||Hospices:3||Clinical trial:3||PanAsian:2||Epidermal growth factor receptor:2||small cell lung cancer:2||Gastric cancer:2||immunotherapy:2||Pemetrexed:2||afatinib:2||NSCLC:2||Smallcell lung cancer:2||tomography:2||trastuzumab:2||treatment:2||Squamous cell carcinoma:2||CTemphysema score:2||Capecitabine:2||breast cancer:2||NonHodgkin lymphoma:2||cancer cachexia:2||muscle:2||metastatic breast cancer:2||Precision medicine:2||Lung cancer:2||Nonsmall cell lung carcinoma:2||Survival:2||Biomarkers:2||Induction chemotherapy:2||Terminal cancer:2||diffuse large Bcell lymphoma:2||Oxaliplatin:2||Drug therapy:2||Metastatic breast cancer:2||Tomography:2||HER2 positive:2||Trastuzumab:2||gastric cancer:2||F18FDG PET/CT:2||EGFR:2||Extranodal NK/Tcell lymphoma:1||Feasibility:1||Ferritin:1||Gastrointestinal stromal tumor:1||Gefitinib:1||GenexolPM:1||Genomic alterations:1||HER2:1||HER2 gene amplification:1||Head and neck neoplasms:1||Hematopoietic stem cell transplantation:1||Histology:1||Hospice:1||Human papillomavirus:1||Hyperglycemia:1||Hypertriglyceridemia:1||Imatinib:1||Immunecheckpoint inhibitor:1||Immunohistochemistry:1||Immunostaining:1||Infection:1||Informed consent:1||Infusionrelated reaction:1||KINDLE Korean subset:1||KIT:1||Ki67:1||Korea:1||Lactate dehydrogenase:1||Locally advanced head and neck cancer:1||Locally advanced head and neck squamous cell carcinoma:1||Lymphoma:1||MAP kinase:1||Medical oncology:1||Metabolic syndrome X:1||Metabolic tumor volume:1||Metabolic tumour volume:1||Molecular targeted therapy:1||Molecular tumor board:1||Multidisciplinary team:1||Multidisciplinary treatment:1||Mutation:1||NGS:1||NOTCH:1||Neutropenia:1||Nintedanib:1||NonSmall Cell Lung Cancer:1||Nonsmall cell lung cancer (NSCLC):1||Nonsmallcell lung cancer:1||Obesity:1||Oropharyngeal neoploasms:1||Outofhospital death:1||PAR framework:1||PDL1:1||POLST:1||Paclitaxel:1||Palliative care:1||Palliative sedation:1||Pancreatic neoplasms:1||Patient satisfaction:1||Patientreported outcome measures:1||Phase II:1||Physician Orders for LifeSustaining Treatment:1||Platinum:1||Portal hypertension:1||Portal vein:1||Positronemission tomography:1||Premenopause:1||Primary cardiac angiosarcoma:1||Prognostic factor:1||Progressionfree survival:1||Quality of life:1||Questionnaire study:1||Radiotherapy:1||Randomized phase II trial:1||Realworld:1||Receptor, epidermal growth factor:1||Resection:1||Risk factor:1||Rituximab:1||STROBE:1||Salvage:1||Screening:1||Secondline:1||Sedative:1||Shared decision making:1||Skeletal muscle:1||Skeletal muscle mass:1||Skin:1||Squamous cell:1||Squamous cell carcinoma of head and neck:1||Squamous cell carcinoma of the head and neck:1||Standardized uptake value:1||Stenosis:1||Stent:1||Stereotactic body radiation therapy:1||Stomach neoplasms:1||Strategy:1||Subsequent treatment:1||Surgery:1||Surrogate decision making:1||Survival analysis:1||TDM1:1||Tamoxifen:1||Terminal care:1||Therapeutics:1||Thrombocytopenia:1||Total lesion glycolysis:1||Trastuzumab biosimilar:1||Treatment outcome:1||Treatment patterns:1||Tumor burden:1||Tyrosine kinase inhibitor:1||Umbrella trial:1||Uterine cervical neoplasms:1||Vinorelbine:1||Vitamin D deficiency:1||acid sphingomyelinase:1||anaplastic thyroid carcinoma:1||belotecan:1||biomarkers:1||biosimilar:1||body composition:1||body mass index:1||brain metastasis:1||cachexia:1||cancer drug:1||ceramide synthase 6:1||chest:1||chromogranin A:1||clinical data warehouse:1||clinical outcome:1||combination:1||computed tomography:1||consensus:1||consultation and referral:1||ctDNA:1||data collection:1||discontinuation:1||dual energy CT:1||duration of treatment:1||durvalumab:1||early stage:1||epidermal growth factor receptor (EGFR):1||erlotinib:1||fertility preservation:1||gefitinib:1||gender:1||guidelines:1||head and neck squamous cell carcinoma (HNSCC):1||healthy:1||ifosfamide:1||immune checkpoint inhibitor:1||inflammation:1||interleukin:1||irAE:1||ki67:1||locally advanced head and neck squamous cell carcinoma:1||locallyadvanced:1||longterm survival:1||lung metastasis:1||medical imaging:1||medical record:1||metabolic tumor volume:1||metastasectomy:1||metastasis:1||neoadjuvant concurrent chemoradiotherapy:1||neoplasm metastasis:1||neuroendocrine tumours:1||neutrophiltolymphocyte ratio:1||nonHodgkin&apos:1||observational study:1||osimertinib:1||p53:1||palliative care:1||pathway analysis:1||pazopanib:1||pectoralis muscle:1||phase Ib:1||positronemission tomography:1||precision medicine:1||preliminary attainability assessment:1||prognostication:1||pseudoprogression:1||quality of life (QoL):1||realworld patient journey:1||refractory:1||relevance:1||reliability:1||s lymphoma:1||sequential treatment:1||serum testosterone:1||skeletal muscle:1||skeletal muscle mass:1||small cell lung cancer (SCLC):1||smallcell lung cancer:1||smoking:1||squamous cell carcinoma:1||stage III NSCLC:1||standardized uptake value:1||surveillance:1||survival:1||survivorship:1||tumour necrosis factoralpha:1||tyrosine kinase inhibitor (TKI):1||uncommon EGFR mutations:1||unresectable:1||wasting:1||young age:1||비타민 D 결핍:1||암:1||18FDG PETCT:1||호스피스:1||Acute myeloid leukemia:1||Advance care planning:1||Advanced solid cancer:1||Adverse event:1||Aged:1||Anemia:1||Antibiotic prophylaxis:1||Artificial intelligence · Multidisciplinary care · Analysis effect.:1||Ascites:1||Bacterial infection:1||Biliary tract cancer:1||Biomarker:1||Bladder cancer:1||Bloodstream infection:1||Bone marrow involvement:1||Brain metastases:1||Breast neoplasm:1||Breast neoplasms:1||Creactive protein:1||CBSJukebox:1||CD99:1||CDK4/6 inhibitor:1||CT emphysema score:1||CTP6:1||Cancer:1||Cancer cachexia:1||Carcinoma, Esophageal neoplasm:1||Carcinoma, nonsmallcell lung:1||Chemoradiotherapy:1||Cisplatin:1||Colorectal neoplasms:1||Computed tomography:1||Continuous deep sedation:1||Core binding factorpositive acute myeloid leukemia:1||CrELfree paclitaxel:1||Deep sedation:1||Diffuse large B cell lymphoma:1||Diffuse large Bcell lymphoma:1||Diffuse large cell lymphoma:1||Dualenergy CT:1||EGFR TKI:1||ESMO:1||ESMO guidelines:1||Early stage nonsmall cell lung cancer:1||Elderly:1||Elderly patients:1||Endocrine therapy:1||Epidermal growth factor ointment:1||Epidermal growth factor receptor mutation:1||ErbB2 receptor:1||Ethanol:1||Ethnic groups:1||Exercise:1||Exon 20:1||

STATISTICS: Total View :3,697,102; Today View :1,314

RSS_1.0 RSS_2.0 ATOM_1.0

1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE